retatrutide peptide brand name Triple Agonist (GLP-1/GIP/GCG) Retatrutide 20mg Lyophilised Solid |

Not a pharmaceutical, medicine, or dietary supplement

10.1016/j.redox.2023.102849 8

Harder because: you lack the deep receptor adaptation that higher-dose tirzepatide users have, meaning the GLP-1 and GIP components of retatrutide may hit you harder than expected at relatively low doses

Treatment stage What may be common What deserves attention Week 1 Nausea, fullness, reduced appetite, bloating, indigestion, diarrhea, constipation, fatigue Repeated vomiting, severe pain, inability to stay hydrated Weeks 2 to 4 Early symptoms may settle, persist, or fluctuate Symptoms interfering with eating, drinking, or daily function Weeks 5 to 8 Symptoms may reappear after clinician-directed dose escalation A significant return or worsening of gastrointestinal symptoms Months 2 to 3 Some patients tolerate treatment more comfortably

Dont worry, they actually check it you arent just shouting into the void

Common adverse events of GLP-1RAs include nausea, vomiting, diarrhea, and constipation, with a significantly higher incidence of nausea than that of placebo [47] [48]